Investigation on the effectiveness of mycophemolate mofeil(MMF) in severe IgA nephropathy with part of renal function

Objective To investigate the effectiveness, safety and the tolerance of mycophemolate mofeil(MMF) and prednisone orally in severe the IgA nephropathy with part of renal function. Methods 30 patients with IgA nephropathy diagnosed by renal biopsy with urinary protein≥1.0g/d and part of renal function but serum creatinine355μmol/L(4mg/dl) were enrolled randomly in the trial. The study group take mycophemolate mofeil dispersible tablets and prednisone orally. The control group only take prednisone orally. 24h urinary protein, glomerular filtration rate, hepatic and renal function were performed before and 3,6,12 months after treatments in both groups. Results 1)After 3 months treatment, decrease of urinary protein were observed in MMF group(P0.01), while in control group no significant changes were found in urinary protein. After treatment for 6 and 12 months, both groups showed obvious decrease of urinary protein. At the 6th and 12th month, the proteinuria in MMF group was significant improved than that in control group (P0.05). 2)After 12 months treatment, decrease of serum creatinine and improvement of renal function were observed in MMF group, while there were no significant changes in control group. Conclusions The therapy of mycopyemolate mofeil and prednisone orally is more effective in reducing proteinuria and protecting renal function than the therapy of prednisone orally in IgA nephropathy with part of renal function. Treatment with MMF associates with less adverse effect and good tolerance.